➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Merck
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,492,441

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,492,441 protect, and when does it expire?

Patent 8,492,441 protects MAYZENT and is included in one NDA.

This patent has forty patent family members in thirty-one countries.

Summary for Patent: 8,492,441
Title:Dosage regimen of an S1P receptor agonist
Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
Inventor(s): Legangneux; Eric (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:12/655,049
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,492,441

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MAYZENT siponimod fumaric acid TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No   Start Trial   Start Trial A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE   Start Trial
Novartis MAYZENT siponimod fumaric acid TABLET;ORAL 209884-002 Mar 26, 2019 RX Yes Yes   Start Trial   Start Trial A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,492,441

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09167209Aug 4, 2009

International Family Members for US Patent 8,492,441

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 074825   Start Trial
Australia 2009331582   Start Trial
Brazil PI0923213   Start Trial
Canada 2747992   Start Trial
Canada 2981830   Start Trial
China 102264363   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Express Scripts
Moodys
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.